|
|
|
| Efficacy of concurrent chemoradiotherapy by irinotecan combined with cisplatin for treating patients with advanced cervical cancer, and its influence on the their pain and quality of life |
| Guangyuan Central Hospital, Guangyuan, Sichuan Province,628000 |
|
|
|
|
Abstract To analyze the clinical efficacy of concurrent chemoradiotherapy by irinotecan combined with cisplatin for treating the patients with advanced cervical cancer, and to study its influence on the pain degree and quality of life of the patients. Methods: The clinical data of 80 patients with advanced cervical cancer from January 2017 to January 2020 were analyzed retrospectively. According to different treatments, these patients were divided into observation group and control group (40 cases in each group). The patients in the control group were treated by concurrent chemoradiotherapy of cisplatin, and the patients in the observation group were treated by concurrent radiochemotherapy of irinotecan combined with cisplatin. The clinical efficacy, pain degree, quality of life, incidence of adverse reactions, and proliferation and apoptosis of tumor cell of the patients were compared between the two groups. Results: The total effective rate of the patients in the observation group (87.5%) was significant higher than that (62.5%) of the patients in the control group (P＜0.05). After treatment, the PANA and A-L1 levels of the patients in both groups had increased significantly, and the improvement of which of the patients in the observation group were significant better than those of the patients in the control group. QCL score of the patients in in both groups had increased significantly, VAS score of the patients in in both groups had decreased significantly, and the improvement of which of the patients in the observation group were significant better than those of the patients in the control group (P＜0.05). Anemia, leukopenia, and neutropenia were observed in the patients in both groups, but there were no significant differences in the incidences of anemia, leukopenia, and neutropenia of the patients between the two groups (P＞0.05). The rates of nausea (26 cases, 65.0%), vomiting (26 cases, 65.0%), and diarrhea (21 cases, 52.5%) of the patients in the observation group were significant higher than those (10 cases, 25.0%; 10 cases, 25.0%; and 12 cases, 30.0%) of the patients in the control group (P＜0.05). Conclusion: Concurrent chemoradiotherapy of irinotecan combined with cisplatin for treating the patients with advanced cervical cancer has good efficacy, which can reduce their pain degree, and can improve their quality of life.
|
|
|
|
|
|
|
|
|
